Trial Profile

A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Copanlisib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Pegfilgrastim (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions

27 Jun 2023 Status changed from active, no longer recruiting to discontinued.
28 Feb 2023 Planned End Date changed from 31 Jul 2025 to 8 Jun 2023.
28 Feb 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com